LAUSR

tin in CD30 cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature. Br J Dermatol 2017; 177:1503– 9. 5 Duvic M, Tetzlaff MT, Gangar P et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol 2015; 33:3759–65. 6 Kim YH, Tavallaee M, Sundram U et al. Phase II investigatorinitiated study of brentuximab vedotin in mycosis fungoides and S ezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol 2015; 33:3750–8. 7 Prince HM, Kim YH, Horwitz S et al. Brentuximab vedotin in patients with CD30-expressing cutaneous T-cell lymphoma versus methotrexate or bexarotene: the phase 3 ALCANZA study. Lancet 2017; 390:555–66. 8 National Institute for Health and Care Excellence. Brentuximab. Available at: https://bnf.nice.org.uk/#Search?q=brentuximab (last accessed 29 September 2017). 9 Trautinger F, Eder J, Assaf C et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/S ezary syndrome. Eur J Cancer 2017; 77:57–74. 10 Scarisbrick J. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management. Future Oncol 2017; 13:2405–11. 11 Quaglino P, Maule M, Prince HM et al. Global patterns of care in advanced stage mycosis fungoides/S ezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol 2017; 28:2517–25.